Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder

European Journal of Neurology

Volumn 24, Issue 1, 2017, Pages 219-226

  Chen, H ^a   Qiu, W ^b   Zhang, Q ^a   Wang, J ^b   Shi, Z ^a   Liu, J ^a   Lian, Z ^a   Feng, H ^a   Miao, X ^a   Zhou, H ^a  

^a SICHUAN UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

annualized relapse rate; azathioprine; disability; mycophenolate mofetil; neuromyelitis optica

Indexed keywords

AMINOTRANSFERASE; AZATHIOPRINE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISOLONE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HAIR LOSS; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENSTRUATION DISORDER; MULTICENTER STUDY; MYELOOPTIC NEUROPATHY; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RASH; RELAPSE; SIDE EFFECT; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; MIDDLE AGED; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AZATHIOPRINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEUROMYELITIS OPTICA; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84996655438     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.13186     Document Type: Article

References (25)

1. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107–1114.
2. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177–189.
3. Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler 2012; 18: 1480–1483.
4. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012; 69: 239–245.
5. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012; 18: 113–115.
6. Azzopardi L, Cox AL, McCarthy CL, Jones JL, Coles AJ. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol 2016; 263: 25–29.
7. Ayzenberg I, Schöllhammer J, Hoepner R, et al. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. J Neurol 2016; 263: 575–582.
8. Kleiter I, Gold R. Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics 2016; 13: 70–83.
9. Kessler RA, Mealy MA, Levy M. Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic. Curr Treat Options Neurol 2016; 18: 2.
10. Kitley J, Palace J. Therapeutic options in neuromyelitis optica spectrum disorders. Expert Rev Neurother 2016; 16: 319–329.
11. Torres J, Pruitt A, Balcer L, Galetta S, Markowitz C, Dahodwala N. Analysis of the treatment of neuromyelitis optica. J Neurol Sci 2015; 351: 31–35.
12. Jeong IH, Park B, Kim SH, Hyun JW, Joo J, Kim HJ. Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints. Mult Scler 2016; 22: 329–339.
13. Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 2014; 71: 324–330.
14. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485–1489.
15. Huh SY, Kim SH, Hyun JW, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 2014; 71: 1372–1378.
16. Chen H, Zhang Y, Shi Z, et al. The efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in Western China. Clin Neuropharmacol 2016; 39: 81–87.
17. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66: 1128–1133.
18. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998; 51: 1219–1220.
19. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011; 77: 659–666.
20. Qiu W, Kermode AG, Li R, et al. Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci 2015; 22: 1178–1182.
21. Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler 2014; 20: 1533–1540.
22. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, Amorin de Souza N, Gabbai AA. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 2010; 67: 1131–1136.
23. Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007; 13: 968–974.
24. Falcini F, Trapani S, Ricci L, et al. Sustained improvement of a girl affected with Devic's disease over 2 years of mycophenolate mofetil treatment. Rheumatology 2006; 45: 913–915.
25. Collongues N, de Seze J. An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica. Ther Adv Neurol Disord 2016; 9: 180–188.